Comparative Pharmacology
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus D H E 45.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus D H E 45.
ALMOTRIPTAN MALATE vs D.H.E. 45
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; cranial vasoconstriction and inhibition of trigeminal nerve transmission.
Dihydroergotamine (DHE) is a semi-synthetic ergot alkaloid that acts as an agonist at serotonin (5-HT1B/1D) receptors, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks. It also has high affinity for alpha-adrenergic receptors and moderate affinity for dopamine D2 receptors.
12.5 mg orally at onset of migraine; may repeat after 2 hours if headache recurs. Maximum 25 mg/day.
1 mg intramuscularly or subcutaneously at first sign of headache, repeat hourly up to 3 mg per day, maximum 6 mg per week.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours. In patients with hepatic impairment, half-life may be prolonged (up to 6-7 hours), necessitating dose adjustment.
2.5 hours (range 2-3.5 hours) for ergotamine; clinical context: short half-life supports its use in acute migraine, but frequent dosing risks ergotism.
Approximately 70% renal excretion (40% unchanged, 30% as metabolites), 30% fecal/biliary elimination.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 90% of elimination, with 10% fecal.
Category C
Category C
Antimigraine Agent
Antimigraine Agent